Premium
Inhibitory effects of Macrolactin A and 7‐O‐succinyl macrolactin A on angiogenesis and cancer cell invasion
Author(s) -
Kang Youra,
Park Sumin,
Kim Hyun Young,
Kim Dong Hee,
Kim Jung-Ae
Publication year - 2012
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.26.1_supplement.48.8
Subject(s) - angiogenesis , chorioallantoic membrane , matrigel , umbilical vein , pharmacology , chemistry , in vivo , sma* , in vitro , inhibitory postsynaptic potential , cancer cell , cancer research , cancer , biology , biochemistry , medicine , endocrinology , microbiology and biotechnology , mathematics , combinatorics
The macrolactin compounds are known to have broad range of pharmacological activities such as antibacterial, anti‐viral, neuro‐protective, and antiproliferative activities. In the present study, we investigated anti‐angiogenic activities of macrolactin A (MA) and its derivatives, 7‐ O ‐malonyl macrolactin A (MMA) and 7‐ O‐ succinyl macrolactin A (SMA) using in vivo chick chorioallantoic membrane (CAM) assay. MA and SMA showed strong inhibitory activity against not only growth factor (VEGF)‐induced but also inflammatory cytokine (TNF‐α and IL‐8)‐induced angiogenesis. However, MMA did not show any inhibitory effect. In in vitro angiogenesis using human umbilical vein endothelial cells (HUVECs), MA and SMA significantly inhibited VEGF‐induced angiogenic processes, proliferation, tube formation and invasion of HUVCs. We also found that MA and SMA concentration‐dependently inhibited HT‐1080 human fibrosarcoma cell invasion in a matrigel‐coated transwell assay. Taken together, our results suggest that MA and SMA may be valuable drug candidates for treating cancer‐ and chronic inflammatory disease‐associated abnormal angiogenesis as well as cancer invasion.